
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics is a clinical-stage biopharmaceutical company with a positive outlook, as they have multiple catalysts ahead including clinical trials and an Investor and Analyst Day scheduled in May 2026. Despite potential dilution from a recent offering, the company's strong balance sheet and differentiated late-stage cough asset, Haduvio, position them for success. However, there are risks to consider, such as clinical and regulatory risk, financing risk, and third-party risk.
Bears say
Trevi Therapeutics is strategically raising capital from a position of clinical momentum with the positive chronic cough data, allowing for improved financial flexibility in funding future development. Additionally, TRVI has plans for a larger Ph 3 study for key secondary endpoints to support an enhanced label and is planning a Ph 2b/3 non-IPF ILD trial in the second half of 2026, with potential launch in 2028. However, there is regulatory risk involved in gaining approval for IPF cough, RCC, and PN.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares